Cargando...
Biomarker Development in the Context of Urologic Cancers
The FDA has called for the use of analytically validated biomarkers that have strong evidence of being fit for purpose to identify patients likely to respond and to evaluate the patient response to a therapy, potential toxicity, and drug resistance. This article discusses development and application...
Gardado en:
| Publicado en: | Urol Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4521394/ https://ncbi.nlm.nih.gov/pubmed/25746942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urolonc.2015.01.007 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|